Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05512910

Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)

This is a multi-center, evaluator-blinded, randomized, open-label, proof of concept trial to explore possible beneficial effect of adjunctive oral minocycline on acute ischemic stroke (AIS) undergoing endovascular treatment due to basilar artery occlusion (BAO). Minocycline has excellent safety profiles, have been previously demonstrated individually to reduce infarction in animal models of stroke, and have potentially mechanisms of antioxidant, anti-inflammatory, anti-apoptotic and protection of blood-brain barrier. However, it is not known whether minocycline can reduce futile recanalization of endovascular treatment, and improve the outcome of patients with AIS due to BAO. Eligible and willing subjects will be randomly assigned to the treatment group or the control group. The treatment group will receive 200 mg oral minocycline, followed by 100 mg every 12 hours times for a total of 5 days. Both groups will receive endovascular thrombectomy and standard medical. The treatment with minocycline will start as soon as possible after randomization. Considering the risk of difficulty in feeding tube before EVT, minocycline administered within one hours after EVT is acceptable. Measures of stroke severity and disability will be recorded at baseline and through the follow-up periods (90 days). The evaluator will be blind to the allocation of patients further minimizing the bias.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Ischemic Stroke, Acute Basilar Artery Occlusion Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Endovascular Treatment Ischemic Stroke Minocycline Nervous System Diseases Stroke Vascular Diseases cyclopia sequence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Neurology, Xijing Hospital, Fourth Military Medical University

Xi'an, Shaanxi, 710032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old.
  • Patients had acute symptoms and signs compatible with ischemia due to basilar artery occlusion (BAO), treated with endovascular therapy. Patients with occlusion of intracranial segments of both vertebral arteries (VA) resulting in no flow to the basilar artery (eg, functional basilar artery occlusion) were also eligible for the study.
  • Last known well to groin puncture between 0 to 24 hours, whether or not patients had thrombolysis with rt-PA.
  • Pre-stroke mRS score of 0-1.
  • Baseline expanded NIHSS (e-NIHSS) score ≥ 6.
  • Signed Informed Consent obtained.
  • Neuroimaging Inclusion Criteria: (1) Proven large vessel occlusion in BAO or VA-V4 occlusion (mTICI score 0-1) determined by MRA or CTA; (2) pc-ASPECTS score ≥ 5 (Non-Contrast CT or DWI); Pons-midbrain-index of<3.

Exclusion criteria

  • Age<18 years old.
  • Complete cerebellar infarct with significant mass effect or has the imaging features of acute hydrocephalus in NCCT.
  • Intracranial hemorrhage.
  • Previous stroke in the past 90 days;
  • cardiopulmonary resuscitation was performed within 10 days prior to onset.
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, INR >3, or platelet<40×109/L.
  • Glucose <2.2 or >22 mmol/L.
  • Systolic blood pressure persistently>185mmHg post-MT despite antihypertensive intervention; Diastolic blood pressure persistently>110mmHg post-MT despite antihypertensive intervention.
  • Acute or chronic renal failure of CKD grade 3-4.
  • Known allergy or hypersensitivity to contrast dye or tetracycline group of drugs.
  • Epileptic seizure at symptom onset.
  • Life expectancy (except for stroke) < 3 months.
  • Female who is pregnancy or breastfeeding, or whom do not use effective contraception at childbearing age.
  • Pre-existing mental illness that interferes with neurological evaluation.
  • Known current participation in another clinical investigation with experimental drug.
  • Unlikely to be available for 90 days follow-up.

Treatment and study plan

Minocycline

Drug

200 mg minocycline orally or via feeding tube, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting. Considering the risk of difficulty in feeding tube before EVT, minocycline administered within one hours after EVT is acceptable.

Other names: Minocycline hydrochloride

Primary outcomes

  1. The expanded NIH Stroke Scale (e-NIHSS) at 5-7 days or at discharge

    Time frame: 5-7 days or discharge after onset

    The primary effectiveness outcome was the e-NIHSS score at 5-7 days or at discharge. 11-item neurologic examination scale for severity of posterior circulation stroke, adding specific elements in existing items of NIHSS.

  2. Incidence of symptomatic intracranial hemorrhage at 24 hours from randomization

    Time frame: 24 hours from randomization

    The primary safety outcome was the incidence of symptomatic intracranial hemorrhage, defined as neurological deterioration (≥4-point increase on the NIHSS score) within 24 hours from randomization and evidence of intracranial hemorrhage on imaging studies.

Secondary outcomes

  1. mRS at 90 (±14) days

    Time frame: 90 (±14) days from randomization

    Secondary outcome measure is the degree of disability or dependence at 90 (±14) days as assessed by the mRS scale. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death.

  2. Good outcome at 90 (±14) days from randomization

    Time frame: 90 (±14) days from randomization

    An mRS score of 0-3 indicated a good outcome, whereas a score of >3 indicated a poor outcome.

  3. Favorable outcome at 90 (±14) days from randomization

    Time frame: 90 (±14) days from randomization

    An mRS score of 0-2 indicated a favorable outcome, whereas a score of >2 indicated a poor outcome.

  4. Excellent outcome at 90 (±14) days from randomization

    Time frame: 90 (±14) days from randomization

    An mRS score of 0-1 indicated an excellent outcome, whereas a score of >1 indicated a poor outcome

  5. NIH Stroke Scale (NIHSS) at 24 hours, 5-7 days or discharge, 30 (±7) days and 90 (±14) days from randomization

    Time frame: 90 (±14) days from randomization

    11-item neurologic examination scale for severity of stroke. Ratings for each item are scored with 3 to 5 grades. A total NIHSS of 0 is normal; 1-4 is considered a minor stroke; 5-15 moderate; 16-20 moderate to severe; and 21-42 severe.

  6. Modified Barthel Index at 30 (±7) days and 90 (±14) days

    Time frame: 30 (±7) days and 90 (±14) days from randomization

    The modified Barthel Index (mBI) is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index score are scored, a higher number being a reflection of greater ability to function independently following hospital discharge.

  7. Incidence of symptomatic intracranial hemorrhage at 3 days from randomization

    Time frame: 3 days from randomization

    The secondary safety outcome was the incidence of symptomatic intracranial hemorrhage, defined as neurological deterioration (≥4-point increase on the NIHSS score) within 3 days from randomization and evidence of intracranial hemorrhage on imaging studies.

  8. Mortality at 90 (±14) days from randomization

    Time frame: 90 (±14) days from randomization

    All-cause mortality occurring within 90 (±14) days follow-up were recorded.

  9. Change in infarct volume from baseline to day 5-7 or discharge

    Time frame: 5-7 days from randomization or discharge

    Changes of infarct volume from baseline (measured by DWI) to day 5-7 or discharge of stroke onset (measured by Flair). Images are processed by imSTROKE software.

  10. Length of Intensive Care Unit (ICU) stay and hospital stay

    Time frame: From the date of admission until discharged from ICU or hospital, up to 4 weeks

    Length of ICU or hospital stay

  11. Pneumonia at 5-7 days or discharge, 30 (±7) days and 90 (±14) days

    Time frame: 90 (±14) days from randomization

    Determine whether rates of pneumonia are different in the two arms. Rates will be measured as percentages of the entire population at risk.

  12. Time of mechanical ventilation or non-invasive ventilation at 5-7 days or at discharge

    Time frame: 5-7 days from randomization or discharge

    Determine whether time of mechanical ventilation or non-invasive ventilation are different in the two arms. Rates will be measured as percentages of the entire population at risk.

  13. Change in hematology assessments: percentage of the lymphocyte subpopulations (%) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    The percentage of lymphocyte subpopulations in % will be assessed by flow cytometry.

  14. Change in hematology assessments: matrix metalloproteinase-9 (ng/ml) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    The level of matrix metalloproteinase-9 in ng/ml will be assessed by ELISA method.

  15. Change in hematology assessments: IL-6 (pg/ml) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    The level of IL-6 in pg/ml will be assessed by ELISA method.

  16. Change in hematology assessments: IL-10 (pg/ml) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    The level of IL-10 in pg/ml will be assessed by ELISA method.

  17. Change in hematology assessments: TNF-α (nmol/L) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    The level of TNF-α in nmol/L will be assessed by ELISA method.

  18. Change in hematology assessments: leucocytes (x 10^9 /L) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    Change in the level of leucocytes x 10^9 /L.

  19. Change in hematology assessments: neutrophilic granulocyte percentage (%) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    Change in the neutrophilic granulocyte percentage in %.

  20. Change in hematology assessments: absolute neutrophil value (x 10^9 /L) at 5-7 days or at discharge as compared to Baseline

    Time frame: 5-7 days from randomization or discharge

    Change in the level of absolute neutrophil value x 10^9 /L.

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Collaborators

  • Central Hospital of Gansu Province
  • First People's Hospital of Xianyang
  • Xi'an Gaoxin Hospital
  • Xi'an No.3 Hospital
  • Xi'an XD Group Hospital

Registry information

Official study title

Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion: a Randomized, Open-label, Proof of Concept Study

Acronym: MIST-B

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 23, 2022
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.